The pharma group says there were no safety concerns with RSVPreF3 OA in the trial either ... is a much bigger market for a potential RSV vaccine however, and accounts for the bulk of GSK's ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV ... to invalidate three GSK patients covering its RSVPreF3 shot, according to a report on the Law360.com ...

Getting the one-dose RSV vaccine is one of the easiest ways to do so. Over the last two years, Oklahoma City has seen an ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Thankfully, there are currently two RSV vaccines approved by the Food and Drug Administration to help people protect against the virus: Arexvy by GlaxoSmithKline and Abrysvo by Pfizer. The Centers for ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically ...

Moderna said on Friday that Canada’s health regulator has approved its vaccine for respiratory syncytial virus (RSV) in adults 60 years and older, making it the country’s first authorized mRNA ...

Go to source) for newborns and pregnant women. Mark Butler, the minister for health, announced 174.5 million Australian dollars ($114.8 million) in funding to subsidize RSV vaccinations following ...

TORONTO - Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — but it won’t be available until next year, the company ...